HALO

Halozyme Therapeutics News

FREE HALO REPORT

Company Name Stock Ticker Symbol Market Type
Halozyme Therapeutics Incorporated HALO NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.00 0.0% 53.28 19:00:00
Open Price Low Price High Price Close Price Prev Close
53.28
more quote information »

Recent News

Date Time Source Heading
1/26/20237:21IHNWFeaturedUCASU jump-starts its plan of NASDAQ or NYSE up-listing in 2023
1/26/202308:54EDGARAmended Statement of Ownership (sc 13g/a)
1/20/202315:04EDGARStatement of Ownership (sc 13g)
1/11/202308:30PRNUSHALOZYME THERAPEUTICS, INC. ANNOUNCES REDEMPTION OF 1.25%..
1/10/202317:15PRNUSHalozyme Provides 2023 Financial Guidance and Outlook
1/04/202318:01EDGARStatement of Changes in Beneficial Ownership (4)
1/03/202308:30PRNUSHalozyme to Present at the 41st Annual J.P. Morgan..
12/13/202218:10EDGARStatement of Changes in Beneficial Ownership (4)
12/12/202215:10EDGARAmended Statement of Ownership (sc 13g/a)
11/17/202217:12EDGARStatement of Changes in Beneficial Ownership (4)
11/17/202217:11EDGARStatement of Changes in Beneficial Ownership (4)
11/14/202207:30TRMNAnalysts Are Bullish on These Healthcare Stocks: AstraZeneca..
11/09/202223:27TRMNHalozyme (HALO) Receives a Buy from SVB Securities
11/09/202208:30PRNUSHalozyme to Participate in Upcoming Investor Conferences
11/09/202200:25TRMNJMP Securities Remains a Buy on Halozyme (HALO)
11/08/202216:08EDGARCurrent Report Filing (8-k)
11/08/202216:01PRNUSHALOZYME REPORTS THIRD QUARTER 2022 FINANCIAL AND OPERATING..
10/31/202200:26TRMNSVB Securities Sticks to Their Buy Rating for Halozyme..
10/25/202208:30PRNUSHalozyme to Report Third Quarter 2022 Financial and..
9/01/202208:30PRNUSHalozyme to Participate in the 2022 Wells Fargo Healthcare..
8/19/202217:24EDGARCurrent Report Filing (8-k)
8/17/202222:36TRMNSVB Securities Keeps Their Buy Rating on Halozyme (HALO)
8/16/202208:43EDGARCurrent Report Filing (8-k)
8/15/202222:32PRNUSHalozyme Therapeutics, Inc. Announces Upsize and Pricing of..
8/15/202207:21EDGARCurrent Report Filing (8-k)
8/15/202207:00PRNUSHalozyme Therapeutics, Inc. Announces Proposed Offering of..
8/10/202223:17TRMNHalozyme (HALO) Gets a Buy from SVB Securities
8/10/202200:40TRMNAnalysts Offer Insights on Healthcare Companies: Halozyme..
8/09/202216:11EDGARCurrent Report Filing (8-k)
8/09/202216:01PRNUSHALOZYME REPORTS SECOND QUARTER 2022 FINANCIAL AND OPERATING..
8/02/202200:55PRNUSPositive Results Announced from Phase III IMscin001 Study..
7/26/202208:30PRNUSHalozyme to Report Second Quarter 2022 Financial and..
6/08/202208:30PRNUSHalozyme to Participate in the Goldman Sachs 43rd Annual..
6/07/202208:30PRNUSHalozyme Announces Commercial Launch of TLANDO™, an Oral..
5/24/202216:18EDGARCurrent Report Filing (8-k)
5/24/202208:30PRNUSHalozyme Completes Antares Pharma Acquisition
5/13/202208:17TRMNJ.P. Morgan Maintains Their Buy Rating on Halozyme (HALO)
5/12/202208:00PRNUSHart-Scott-Rodino Waiting Period Expires for Halozyme's..
5/10/202216:19EDGARQuarterly Report (10-q)
5/10/202216:09EDGARCurrent Report Filing (8-k)
5/10/202216:01PRNUSHalozyme Reports First Quarter 2022 Results
5/06/202216:12EDGARCurrent Report Filing (8-k)
5/03/202214:20PRNUSHalozyme To Host First Quarter 2022 Financial Results..
4/26/202208:00PRNUSHALOZYME COMMENCES TENDER OFFER FOR ALL OUTSTANDING SHARES..
4/13/202213:35TRMNJMP Securities Sticks to Its Buy Rating for Halozyme (HALO)
4/13/202206:00PRNUSHalozyme to Acquire Antares Pharma to Create a Specialty..
3/24/202216:55EDGARInitial Statement of Beneficial Ownership (3)
3/24/202208:52SEEKHalozyme Therapeutics licenses ENHANZE drug delivery..
3/24/202208:00PRNUSHalozyme Therapeutics, Inc. and Chugai Pharmaceutical Enter..
3/22/202202:15PRNUSPositive Topline Results Announced from ADAPT-SC Study..
3/15/202216:51EDGARCurrent Report Filing (8-k)